<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>ME-E Internal request:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on the recent FDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>approval, review the data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for dabrafenib for inclusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in the NCCN Guidelines for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma as a systemic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapy option for the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment of advanced or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metastatic melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based upon panel discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and the noted reference,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>the panel consensus was to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>add dabrafenib as a category 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>recommendation under the list</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of “Preferred Regimens” for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>the treatment of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with advanced or metastatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>melanoma.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hauschild A, Grob JJ,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demidov LV, et al. Dabrafenib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in BRAF-mutated metastatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>melanoma: a multicentre,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>open-label, phase 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>randomised controlled trial.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ME-E Internal request:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on the recent FDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>approval, review the data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for trametinib for inclusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in the NCCN Guidelines for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma as a systemic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapy option for the</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment of advanced or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metastatic melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based upon panel discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and the noted reference,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>the panel consensus was to</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>add trametinib as a category 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>recommendation under the list</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of “Other Active Regimens”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for the treatment of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with advanced or metastatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>melanoma.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flaherty KT, Robert C,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hersey P, et al. Improved</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival with MEK Inhibition</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in BRAF-mutated melanoma.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>